ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.

Langerhorst P, et al.
Clinical Chemistry
November 2021
Authors and Affiliates
Pieter Langerhorst,a, Somayya Noori ,b, Marina Zajec,b,c Yolanda B. De Rijke,c Jolein Gloerich,a Alain J. van Gool,a He´le`ne Caillon,d Irma Joosten,a Theo M. Luider,b Jill Corre,e Martijn M. VanDuijn,b, Thomas Dejoie,d, and Joannes F.M. Jacobsa aDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; bDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; cDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands; dLaboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France; eUnite de Genomique du Myelome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.